Isolation from cannabis sativa L. of cannflavin—a novel inhibitor of prostaglandin production

doi:10.1016/0006-2952(85)90325-9

Biochemical Pharmacology

Volume 34, Issue 11, 1 June 1985, Pages 2019-2024

https://doi.org/10.1016/0006-2952(85)90325-9 Get rights and content

Abstract

The isolation from Cannabis sativa L. of an inhibitor of prostaglanclin (PG) E₂ production by cultured rheumatoid synovial cells is described. This agent, for which the name Cannflavin has been coined, is distinct from cannabinoids on the basis of isolation procedure, preliminary structural analysis and biological properties. The activity of Cannflavin has been compared with several established anti-inflammatory drugs and the major cannabinoids.

References (17)

S. Burstein et al.
Biochem. Pharmac.
(1973)
S. Burstein et al.
Biochem. Pharmac.
(1982)
J. Baumann et al.
Prostaglanclins
(1980)
W.B. O'Shaughnessy
Trans. med. phys. Soc. Calcutta
(1842)
L.S. Harris et al.
J.F. Howes et al.
G.P. Lewis
Br. med. Bull.
(1983)
M.L. Barret et al.
J. pharm. Pharmac.
(1982)

There are more references available in the full text version of this article.

Cited by (62)

A validated method for detection of cannflavins in hemp extracts
2023, Journal of Pharmaceutical and Biomedical Analysis
A selective and sensitive liquid chromatography mass spectrometry assay was developed for the detection of cannflavin A, B, and C in hemp extract specimens. A deuterated analog cannabidiol-D3 was used as the internal standard and the isocratic method used a mobile phase consisting of acetonitrile and water with 0.1 % formic acid [83:17]. Detection was carried out by electrospray positive ionization in single-ion monitoring mode through a C-18 analytical column. The assay (total run time <20 min) had excellent linearity and a lower limit of quantification of 0.5 μg/mL and a limit of detection of 0.25 μg/mL with a 10 μL injection. The method possessed suitable measures of stability, sensitivity, and selectivity for detecting cannflavins in several specimen types. The method was successfully applied to the analysis of samples of cannflavin release from prototype topical formulations.
Untargeted cannabinomics reveals the chemical differentiation of industrial hemp based on the cultivar and the geographical field location
2023, Analytica Chimica Acta
Cannabis sativa has long been harvested for industrial applications related to its fibers. Industrial hemp cultivars, a botanical class of Cannabis sativa with a low expression of intoxicating Δ⁹-tetrahydrocannabinol (Δ⁹-THC) have been selected for these purposes and scarcely investigated in terms of their content in bioactive compounds. Following the global relaxation in the market of industrial hemp-derived products, research in industrial hemp for pharmaceutical and nutraceutical purposes has surged. In this context, metabolomics-based approaches have proven to fulfill the aim of obtaining comprehensive information on the phytocompound profile of cannabis samples, going beyond the targeted evaluation of the major phytocannabinoids. In the present paper, an HRMS-based metabolomics study was addressed to seven distinct industrial hemp cultivars grown in four experimental fields in Northern, Southern, and Insular Italy. Since the role of minor phytocannabinoids as well as other phytocompounds was found to be critical in discriminating cannabis chemovars and in determining its biological activities, a comprehensive characterization of phytocannabinoids, flavonoids, and phenolic acids was carried out by LC-HRMS and a dedicated data processing workflow following the guidelines of the metabolomics Quality Assurance and Quality Control Consortium. A total of 54 phytocannabinoids, 134 flavonoids, and 77 phenolic acids were annotated, and their role in distinguishing hemp samples based on the geographical field location and cultivar was evaluated by ANOVA-simultaneous component analysis. Finally, a low-level fused model demonstrated the key role of untargeted cannabinomics extended to lesser-studied phytocompound classes for the discrimination of hemp samples.
Interference of neuronal TrkB signaling by the cannabis-derived flavonoids cannflavins A and B
2023, Phytomedicine Plus
Cannflavins A and B are flavonoids that accumulate in the Cannabis sativa plant. These specialized metabolites are uniquely prenylated and highly lipophilic, which may permit their interaction with membrane-bound enzymes and receptors. Although previous studies found that cannflavins can produce anti-inflammatory responses by inhibiting the biosynthesis of pro-inflammatory mediators, the full extent of their cellular influence remains to be understood. Here, we studied these flavonoids in relation to the Tropomyosin receptor kinase B (TrkB), a receptor tyrosine kinase that is activated by the growth factor brain-derived neurotrophic factor (BDNF). Using mouse primary cortical neurons, we first collected evidence that cannflavins prevent the accumulation of Activity-regulated cytoskeleton-associated (Arc) protein upon TrkB stimulation by exogenous BDNF in these cells. Consistent with this effect, we also observed a reduced activation of TrkB and downstream signaling effectors that mediate Arc mRNA transcription when BDNF was co-applied with the cannflavins. Of note, we also performed a high-throughput screen that demonstrated a lack of agonist action of cannflavins towards 320 different G protein-coupled receptors, a result that specifically limit the possibility of a TrkB transinactivation scenario via G protein signaling to explain our results with dissociated neurons. Finally, we used Neuro2a cells overexpressing TrkB to show that cannflavins can block the growth of neurites and increased survival rate produced by the higher abundance of the receptor in this model. Taken together, our study offers a new path to understand the reported effects of cannflavins and other closely related compounds in different cellular contexts.
Cannflavins – From plant to patient: A scoping review
2020, Fitoterapia
Citation Excerpt :
Cannflavins were first identified in 1980 by Crombie et al. who uniquely isolated CFL-A and CFL-B from Cannabis sativa L. [10]. In a collection of studies published during 1985 and 1986, Barret et al. studied the ability of both compounds to inhibit prostaglandin E2 (PGE2) release from human rheumatoid synovial cells, demonstrating potency 30 times that of aspirin in an ex vivo setting [11,12]. There is an ongoing need for development of novel anti-inflammatory medications in the setting of rising incidence of inflammatory and auto-immune conditions globally [13].
Cannflavins are a group of prenylflavonoids derived from Cannabis sativa L.. Cannflavin A (CFL-A), B (CFL-B) and C (CFL-C) have been heralded for their anti-inflammatory properties in pre-clinical evaluations. This scoping review aims to synthesise the evidence base on cannflavins to provide an overview of the current research landscape to inform research strategies to aid clinical translation.
A scoping review was conducted of EMBASE, MEDLINE, Pubmed, CENTRAL and Google Scholar databases up to 26th February 2020. All studies describing original research on cannflavins and their isomers were included for review.
26 full text articles were included. CFL-A and CFL-B demonstrated potent anti-inflammatory activity via inhibition of 12-o-tetradecanoylphorbol 13-acetate induced PGE2 release (CFL-A half maximal inhibitory concentration (IC50): 0.7 μM; CFL-B IC50: 0.7 μM) and microsomal prostaglandin E synthase-1 (CFL-A IC50: 1.8 μM; CFL-B IC50: 3.7 μM). Outcomes were also described in preclinical models of anti-oxidation (CFL-A), anti-parasitic activity (CFL-A, CFL-C), neuroprotection (CFL-A) and cancer (Isocannflavin B, a CFL-B isomer). In-silico screening identified that CFL-A has binding affinity with viral proteins that warrant further investigation.
Cannflavins demonstrate a number of promising therapeutic properties, most notably as an anti-inflammatory agent. Low yields of extraction however have previously limited research to small pre-clinical investigations. Identification of cannflavin-rich chemovars, novel extraction techniques and recent identification of a biosynthetic pathway will hopefully allow research to be scaled appropriately. In order to fully evaluate the therapeutic properties of cannflavins focused research now needs to be embedded within institutions with a track-record of clinical translation.
Medicinal cannabis: Pharmaceutical forms and recent analytical methodologies
2020, Comprehensive Analytical Chemistry
The use and study of medicinal cannabis is growing in accordance with the changes in the laws of many countries, along with the technological advances that allowed expanding the knowledge about its multiple pharmacological properties. Exhaustive studies on the pharmacological effects of the different Cannabis sativa constituents are of great importance due to the high impact that this ancient plant has on biological systems. Besides, the pharmaceutical form used for their administration is one of the relevant factors determining the absorption of phytocannabinoids by the human body, the physiological effects and their behaviour in relation to the nature of the analysed organic matrices, either for medicinal or legal purposes. This chapter summarizes the activity of phytocannabinoids on their specific receptors in mammals and the processes that they undergo in the body. The traditional and novel pharmaceutical formulations and the analytical methodologies to evaluate the organic matrices exposed to cannabis are also reviewed.
Analysis of Phytocannabinoids in Hemp Seeds, Sprouts and Microgreens
2023, SSRN

View all citing articles on Scopus

View full text

Isolation from cannabis sativa L. of cannflavin—a novel inhibitor of prostaglandin production

Abstract

Biochem. Pharmac.

Biochem. Pharmac.

Prostaglanclins

Trans. med. phys. Soc. Calcutta

Br. med. Bull.

J. pharm. Pharmac.